ORICORIC PharmaceuticalsSigning up patients
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Solid Tumors
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 350 (planned)
- Started
- Mar 10, 2022
- Main results expected
- Jun 2027
- Fully finished
- Jun 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recommended Phase 2 Dose (RP2D)
Measured over: 12 months
Maximum plasma concentration (Cmax)
Measured over: 28 Days
Time of maximum observed concentration (Tmax)
Measured over: 28 Days
Area under the curve (AUC)
Measured over: 28 Days
Apparent plasma terminal elimination half-life (t1/2)
Measured over: 28 Days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05315700 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC